Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06934642 · ClinicalTrials.gov registry record · Early Phase 1
Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
A Early Phase 1 study of Obesity and MASLD, sponsored by University of New Mexi.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT06934642 is a Early Phase 1 study of Obesity and MASLD that is actively recruiting participants, run by University of New Mexi. The registered enrollment target is 8 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06934642, a Early Phase 1 study of Obesity and MASLD, is actively recruiting participants, sponsored by University of New Mexi.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease. Tirzepatide is a medication used to treat type 2 diabetes and obesity. It has also been shown to help with MASLD. The purpose of this study is to study how tirzepatide affects the liver in patients with MASLD. Participants will be asked to: * Take tirzepatide for 12 months. * Come in for clinic visits every 3 months. * Have blood drawn at baseline, 6, and 12 months. * Complete a liver ultrasound at baseline and at 12 months.
Interventions
- DRUG Tirzepatide
Study Locations (1)
New Mexico
- University of New Mexico Health Sciences Center - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2025-06-30 |
| Est. Completion | 2026-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06934642
The ClinicalTrials.gov registry entry for NCT06934642 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower). The listed sponsor is University of New Mexi, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Tirzepatide is the first listed.
NCT06934642 reports 1 study location spanning 1 distinct geographic area - top geographies include New Mexico.
Frequently Asked Questions
What is clinical trial NCT06934642 about?
NCT06934642 is a clinical study titled "Effect of Tirzepatide on Markers of MASLD in Patients With Obesity". Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease. Tirzepatide is a medication used to treat ...
What is the current status of trial NCT06934642?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2025-06-30. Estimated completion is 2026-08.
What conditions does trial NCT06934642 study?
This clinical trial studies the following conditions: Obesity, MASLD.
What interventions are being tested in trial NCT06934642?
The interventions under investigation include: Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06934642?
This trial is sponsored by University of New Mexi, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06934642 being conducted?
This trial has 1 study location across New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation
RECRUITING · Early Phase 1
-
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
RECRUITING · Early Phase 1
-
Social Determinants of Sleep and Obesity
RECRUITING · Early Phase 1
-
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
RECRUITING · Early Phase 1
-
Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity
RECRUITING · Early Phase 1
-
Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.